Business Context and Reporting Period
This Form 8-K reports on the results of the 2023 Annual Meeting of Stockholders held by MEDICINOVA, INC. on June 13, 2023. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market under the symbol MNOV.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
At the record date of April 19, 2023, the company had 49,046,246 shares of common stock issued and outstanding. A quorum was established with 31,299,321 shares present. The following matters were voted upon:
- Election of Director: Hideki Nagao was elected as a Class I Director to serve until the 2026 Annual Meeting.
- For: 19,685,986
- Against: 7,517,392
- Abstain: 1,380,430
- Broker Non-Vote: 2,715,513
- Ratification of Auditors: The selection of BDO USA, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023, was approved.
- For: 27,807,178
- Against: 2,362,900
- Abstain: 1,129,243
- Equity Incentive Plan: The 2023 Equity Incentive Plan was approved.
- For: 19,200,437
- Against: 7,879,289
- Abstain: 1,504,082
- Broker Non-Vote: 2,715,513
Guidance, Outlook, and Risks
This filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It strictly details the procedural outcomes of the annual shareholder meeting.
Investor Verification Checklist
- Verify the definitive proxy statement filed on April 26, 2023, for detailed background on the director nominee and the equity incentive plan.
- Review the most recent 10-K or 10-Q filings for financial performance metrics, as this 8-K contains no financial data.
- Confirm the term of the newly elected director, Hideki Nagao, extends through the 2026 Annual Meeting.
- Note the significant number of "Against" votes for the director election and the equity plan, which may warrant review of shareholder dissent reasons in the proxy statement.